Vietnam and Pfizer partner to boost vaccine production
Summary and headline written by AI from the source article. How we work
In New York City, Party General Secretary and State President To Lam observed the signing of a cooperation agreement between VNVC, a Vietnamese vaccination center system, and Pfizer, a U.S. biopharmaceutical company.
The two organizations plan to work together to improve Vietnam’s ability to vaccinate its population and prevent diseases.
Pfizer will share its expertise to help VNVC build a vaccine manufacturing plant in Vietnam that meets international standards, with the goal of producing vaccines for both local use and export. VNVC is also building a large vaccine manufacturing plant in Tay Ninh Province, Vietnam, investing more than VND2.5 trillion (US$96.12 million) in the first phase of the project. The plant, which will span over 26,000 square meters, is designed to produce approximately 100 to 120 million vaccine doses annually.
VNVC anticipates completing construction and beginning vaccine production by 2029. Beyond Pfizer, VNVC is collaborating with several other international pharmaceutical companies, including GSK from the United Kingdom and Russian organizations, to expand Vietnam’s vaccine manufacturing capabilities. VNVC recently informed leaders from Vietnam and France about its progress in developing next-generation vaccines with Sanofi, a French company, marking the first such cooperation in Southeast Asia.
They plan to prioritize the production of a six-in-one vaccine, a seasonal influenza vaccine, and a vaccine against meningococcal disease, with initial production expected in 2028.
